Diabetes Care, Vol 23, Issue 5 675-681, Copyright © 2000 by American Diabetes Association

ARTICLES

Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency

CB Juhl, N Porksen, M Hollingdal, J Sturis, S Pincus, JD Veldhuis, A Dejgaard and O Schmitz
Department of Medicine M (Endocrinology & Diabetes), Arhus Kommunehospital, University Hospital of Arhus, Denmark. cbj@dadlnet.dk

OBJECTIVE: Repaglinide is a new oral hypoglycemic agent that acts as a prandial glucose regulator proposed for the treatment of type 2 diabetes by stimulating insulin secretion. The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series. RESEARCH DESIGN AND METHODS: We examined 8 healthy lean male subjects in a single-dose double-blind placebo-controlled crossover design. After the subjects underwent an overnight fast, blood sampling was initiated and continued every minute for 120 min. After 40 min, a single dose (0.5 mg) of repaglinide or placebo was given. Serum insulin-concentration time series were assessed by deconvolution analyses and the regularity statistic by approximate entropy (ApEn). RESULTS: Average insulin concentration was increased after repaglinide administration (basal vs. stimulated period, P values are placebo vs. repaglinide) (25.1 +/- 3.6 vs. 33.5 +/- 4.1 pmol/l, P < 0.001). Insulin secretory burst mass (15.8 +/- 2.2 vs. 19.6 +/- 2.8 pmol x l(-1) x pulse(-1), P = 0.02) and amplitude (6.1 +/- 0.9 vs. 7.7 +/- 1.2 pmol x l(-1) x min(-1), P = 0.008) were augmented after repaglinide administration. A concomitant trend toward an increase in basal insulin secretion was observed (2.5 +/- 0.3 vs. 3.2 +/- 0.4 pmol x l(-1) x min(-1), p = 0.06), while the interpulse interval was unaltered (6.8 +/- 1.0 vs. 5.4 +/- 0.4 min/pulse, P = 0.38). ApEn increased significantly after repaglinide administration (0.623 +/- 0.045 vs. 0.670 +/- 0.034, P = 0.04), suggesting less orderly oscillatory patterns of insulin release. CONCLUSIONS: In conclusion, a single dose of repaglinide amplifies insulin secretory burst mass (and basal secretion) with no change in burst frequency. The possible importance of these mechanisms in the treatment of type 2 diabetes characterized by disrupted pulsatile insulin secretion remains to be clarified.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Bertuzzi, S. Salinari, and G. Mingrone Insulin granule trafficking in beta-cells: mathematical model of glucose-induced insulin secretion Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E396 - E409. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. D. Veldhuis, and P. C. Butler The mass, but not the frequency, of insulin secretory bursts in isolated human islets is entrained by oscillatory glucose exposure Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E750 - E756. [Abstract] [Full Text] [PDF]

				A. Caumo and L. Luzi First-phase insulin secretion: does it exist in real life? Considerations on shape and function Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E371 - E385. [Abstract] [Full Text] [PDF]

				C. B. Juhl, M. Hollingdal, N. Porksen, A. Prange, F. Lonnqvist, and O. Schmitz Influence of Rosiglitazone Treatment on {beta}-Cell Function in Type 2 Diabetes: Evidence of an Increased Ability of Glucose to Entrain High-Frequency Insulin Pulsatility J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3794 - 3800. [Abstract] [Full Text] [PDF]

				C. B. Juhl, N. Porksen, S. M. Pincus, A. P. Hansen, J. D. Veldhuis, and O. Schmitz Acute and Short-Term Administration of a Sulfonylurea (Gliclazide) Increases Pulsatile Insulin Secretion in Type 2 Diabetes Diabetes, August 1, 2001; 50(8): 1778 - 1784. [Abstract] [Full Text] [PDF]